Intellipharmaceutics International Inc. (IPCI) Announces Quarterly Earnings Results
Intellipharmaceutics International Inc. (NASDAQ:IPCI) issued its quarterly earnings results on Friday. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.07). Intellipharmaceutics International had a negative return on equity of 832.00% and a negative net margin of 325.20%.
Shares of Intellipharmaceutics International (NASDAQ:IPCI) opened at 2.90 on Friday. Intellipharmaceutics International has a 1-year low of $1.41 and a 1-year high of $3.33. The company’s market cap is $83.37 million. The company has a 50 day moving average of $2.06 and a 200 day moving average of $1.86.
Several brokerages have recently issued reports on IPCI. Zacks Investment Research downgraded Intellipharmaceutics International from a “hold” rating to a “sell” rating in a research report on Thursday. Brean Capital reaffirmed a “buy” rating and issued a $8.00 price target on shares of Intellipharmaceutics International in a research report on Tuesday, July 5th. Finally, Maxim Group reaffirmed a “buy” rating on shares of Intellipharmaceutics International in a research report on Friday, July 22nd.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/14/intellipharmaceutics-international-inc-ipci-announces-quarterly-earnings-results.html
Intellipharmaceutics International Company Profile
Intellipharmaceutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.